相关实验视频

Updated: Mar 9, 2026

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

理性和in silico引导的APOBEC3F导向的CBE用于增强的PDAC基因疗法

Qingxiao Fang¹, Jin Zhang¹, Keshan Wang²

¹Pancreas Center, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Communications biology

|March 7, 2026

概括

研究人员使用进化规模建模和结构导向突变生成开发了先进的细胞因子基编辑器 (CBEs). 这些新型CBE显示出潜在的癌症基因治疗的增强精度和效率,在胰腺癌模型中有效地沉默瘤基因.

科学领域:

生物化学生物化学
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

细胞酶基编辑器 (CBEs) 提供精确的C-to-T转换,具有治疗潜力.
在瘤学中CBE的应用需要进一步的探索和优化.

研究的目的:

通过使用进化规模建模 (ESM) 和结构导向突变发生,设计基于人类APOBEC3F (A3F) 的高性能CBEs.
评估开发的A3F-CBEs的效率,准确性和特异性.
在胰腺管道腺癌 (PDAC) 的临床前模型中证明A3F-CBEs的治疗疗效.

主要方法:

进化规模建模 (ESM) 与结构导向突变发生的整合,以重塑人类APOBEC3F (A3F).
描述在不同位置的目标编辑效率和特异性.
在PDAC模型中使用双AAV传递平台进行体外和体内测试,针对PDAC模型中的KRAS和MYC瘤基因.

主要成果:

与现有的A3A和Anc689-BE4max系统相比,设计的A3F-CBE显示出明显更高的目标编辑效率.
开发的A3F-CBEs在不损害特异性的情况下显示出比haA3A-G更好的准确性.
双AAV输送的A3F-BE4max有效地沉默了瘤基因,抑制了PDAC细胞增殖在体外和患者衍生器官 (PDO) 中,并抑制了体内瘤生长,延长了生存时间.

结论:

以ESM为指导的工程产生了基于A3F的高效和准确的CBE.
A3F-CBEs代表了用于癌症基因治疗的多功能和精确的平台.
开发的CBEs在胰腺管道腺癌治疗中显示出显著的治疗前景.

更多相关视频

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Published on: March 5, 2017

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...